Arthneeti

Valiant Laboratories Q2 FY27 Share Price & Earnings Call Analysis

₹123.33-1.99% today
Market cap
₹670 Cr
P/E
41.87
ROE
-2.55%
Price to sales
2.19
Debt to equity
0.15
52W high / low
₹141 / ₹50.9
EBITDA margin
10.87%
Net profit margin
-2.93%
Promoter holding
74.94%
Sales (last year)
₹306 Cr

Incorporated in 1980, Valiant Laboratories Ltd manufactures and deals in Pharmaceuticals and speciality chemicals[1]

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Strong growth
    3
See all potential multibaggersWhere does Valiant Laborato rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹480 Cr19.1
240%+Up 0–2%₹212 Cr16.1
340%+Flat₹17,925 Cr—
440%+Flat₹5,223 Cr39.1
540%+Flat₹4,268 Cr—
640%+Flat₹40 Cr—

Sign up free to see every company in the sector ranking and track Valiant Laborato.

Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology ranking

Financials of Valiant Laborato

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Shareholder Pattern

Valiant Laborato

Shareholding breakup across reporting periods.

Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Promoters +74.94%74.94%74.94%74.94%74.94%74.94%74.94%74.94%74.94%74.94%74.94%74.94%
FIIs +7.08%3.48%1.89%0.00%0.00%0.64%0.63%0.02%0.01%0.20%0.00%0.07%
DIIs +0.43%0.00%0.00%0.00%0.00%0.00%0.46%0.00%0.00%0.00%0.00%0.08%
Public +17.54%21.58%23.18%25.06%25.06%24.42%23.97%25.05%25.05%24.87%25.06%24.91%
No. of Shareholders15,82114,91414,24915,18915,69215,03614,43215,07514,91014,65714,34114,618

Financials of Valiant Laborato

Quarterly Results

Quarter-by-quarter operating performance

Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales +59.5540.5230.5918.8821.4835.2357.7946.8246.2052.4691.98115.29116.77
Expenses +60.9446.8335.1221.2728.2234.6153.9744.4346.1253.3587.1786.03111.59
Operating Profit-1.39-6.31-4.53-2.39-6.740.623.822.390.08-0.894.8129.265.18
OPM %-2.33%-15.57%-14.81%-12.66%-31.38%1.76%6.61%5.10%0.17%-1.70%5.23%25.38%4.44%
Other Income +2.961.782.502.813.361.58-2.310.660.870.630.170.860.11
Interest0.020.020.020.050.010.060.050.070.140.681.011.070.96
Depreciation0.490.490.520.530.520.520.520.530.532.052.932.863.66
Profit before tax1.06-5.04-2.57-0.16-3.911.620.942.450.28-2.991.0426.190.67
Tax %25.47%-30.75%-51.75%218.75%21.23%-44.44%25.53%25.71%25.00%136.12%-68.27%19.43%37.31%
Net Profit +0.79-3.50-1.24-0.51-4.742.350.701.820.20-7.061.7621.100.41
EPS in Rs0.23-0.75-0.26-0.11-1.010.500.150.390.04-1.300.323.880.08

Financials of Valiant Laborato

Profit & Loss

Annual income statement trend

Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales +334182133237376
Expenses +299190138231338
Operating Profit35-8-5638
OPM %11%-4.6%-3.5%2.7%10%
Other Income +510522
Interest00024
Depreciation222612
Profit before tax38-1-2125
Tax %24%-142%46%525%
Net Profit +290-2-316
EPS in Rs8.260.07-0.47-0.602.98
Dividend Payout %0%0%0%0%

Financials of Valiant Laborato

Balance Sheet

Capital structure and asset base

Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital3343435454
Reserves68193191257278
Borrowings +60771224638
Other Liabilities +52294510784
Total Liabilities213343401464454
Fixed Assets +485048227226
CWIP14315666
Investments343802635
Other Assets +130212197205187
Total Assets213343401464454

Financials of Valiant Laborato

Cash Flows

Operating, investing and financing cash movement

Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +5621-10
Cash from Investing Activity +-55-144-537
Cash from Financing Activity +-1152452
Net Cash Flow-010-7-1
Free Cash Flow18-44-112-45
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit185%-11%25%-147%

Financials of Valiant Laborato

Ratios

Working capital efficiency and return ratios

Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days9792197144
Inventory Days17221384
Days Payable6256128175
Cash Conversion Cycle52578253
Working Capital Days70106156116
ROCE %-2%-1%1%
46out of 100

Momentum score · price trend

46 out of 100 — Steady

Over the past year its share price has moved roughly in the middle of the stocks we track.

PeriodShare price changeBetter than … of 1,910 stocks
Last 12 months+52.1%86%
Last 6 months+64.5%93%
Last 3 months+103.8%100%

The price is 34.2% below its all-time high of ₹191.23 (20 Jan 2024). Stocks more than 20% below their peak have their score halved, so 92 became 46.

How we calculate it

“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).

The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Valiant Laborato: 0.4 × 86 + 0.4 × 93 + 0.2 × 100 = 92, halved to 46 because the price is more than 20% below its all-time high.

Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.

Full methodology →

This describes only how the share price has moved up to 2 Nov 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.

Continue your research

What Valiant Laborato's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Anthem Bioscienc (Q2 FY27)

    Q2FY27 Consolidated Revenue from Operations: ₹5,940 Mn, up 7.9% YoY from ₹5,505 Mn in Q2FY26 (Page 4). Key investor presentation takeaways from Anthem Bioscienc

  • Neuland Laboratories (Q2 FY27)

    Q2FY27 Total Income (revenue) was ₹457.2 crore, down 11.4% year-on-year (YoY) from Q2FY26. Key investor presentation takeaways from Neuland Laboratories Ltd's Q

  • Hikal (Q2 FY27)

    Consolidated Revenue Q2FY27:** ₹434 crores, up 36% YoY from ₹319 crores in Q2FY26 (Page 9) . Key investor presentation takeaways from Hikal Ltd's Q2 FY27 invest

  • Kopran (Q2 FY27)

    9,335 lakhs (~79% increase) . Key investor presentation takeaways from Kopran Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.

Compare:vs Sun Pharmaceutical Industriesvs Divis Laboratoriesvs Torrent Pharmaceuticals